Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Summary

This is a single arm study, conducted at two centers, of neoadjuvant sotorasib in treatment naïve patients with stage Ib-IIIa NSCLC. The study will accrue 25 patients in all. Patients must have been deemed surgically resectable and physiologically fit for surgery by a thoracic surgeon prior to enrollment.

Timeline

Start

2022-07-13

Primary completion

2024-01-01

Completion

2024-02-01

Drugs

Indications